EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma

The use of daratumumab in combination with established regimens for the treatment of newly diagnosed multiple myeloma has recently been authorized by the European Medicines Agency based on results from three separate phase III randomized, active controlled, open‐label studies that have confirmed enh...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2020-12, Vol.25 (12), p.1067-1074
Hauptverfasser:	Michaleas, Sotirios, Penninga, Elisabeth, Hovgaard, Doris, Dalseg, Anne‐Marie, Rosso, Aldana, Sarac, Sinan B., Jimenez, Jorge Camarero, Fernández, Lucia López‐Anglada, Fernández, Carolina Prieto, Mangas‐SanJuan, Victor, Garcia, Isabel, Payares‐Herrera, Concepcion, Sancho‐López, Aranzazu, Enzmann, Harald, Castro Lopes Silva, Marcia Sofia Sanches, Duarte, Sílvia, Pignatti, Francesco
Format:	Artikel
Sprache:	eng
Schlagworte:	Daratumumab European Medicines Agency Newly diagnosed multiple myeloma Regulatory Issues: EMA
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!